Mittie Doyle

Chief Medical Officer

​

Mittie Doyle, MD, FACR is a proven research physician who has held numerous leadership roles in clinical development. She brings over 20 years of experience in the pharmaceutical/biotech industry and academia to her role as chief medical officer at Aro and most recently served as Vice President, Global Therapeutic Area Head, Research & Development, Immunology at CSL Behring.  Prior to her time at CSL, Dr. Doyle held senior level roles at Shire Pharmaceuticals, Flexion Therapeutics and Alexion Pharmaceuticals; during her career, she has led clinical development across a broad range of immune mediated and orphan diseases.  She has led teams with responsibilities for design and execution of first-in-human through phase 2 and 3 trials, resulting in several global regulatory approvals.  Dr. Doyle received her BA magna cum laude from Princeton University in Romance Languages and her MD cum laude from Yale Medical School. She completed her postdoctoral training at Harvard Medical School including residency in Internal Medicine at Massachusetts General Hospital and clinical/research fellowship in Rheumatology and Immunology at Brigham and Women’s Hospital.